RxDoctor Payments Data

Eric Caywood, DO

Family Medicine · Jefferson City, MONPI 1194722371

Payments from drug & device makers

$13,045in general payments, 2019–2025

Across 884 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Amgen$762
  • Lilly USA, LLC$611
  • plus $6K from 54 others

What the payments were for

  • Consulting fees$1751%
  • Speaking & faculty fees$600%
  • Food & beverage$12,40695%
  • Education$4043%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)161$2,091
AstraZeneca68$1,343
Novo Nordisk97$1,149
Pfizer95$1,022
Amgen(2 entities)39$762
Lilly USA, LLC43$611
Astellas Pharma US Inc20$569
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC21$346
Johnson & Johnson24$345
Takeda Pharmaceuticals U.S.A., Inc.24$339
Abbott24$303
Boehringer Ingelheim20$292
Amarin Pharma, Inc.15$282
Merck15$237
Biohaven Pharmaceuticals, Inc.21$234
Teva Pharmaceuticals USA, Inc.15$224
Otsuka America Pharmaceutical, Inc.13$218
GSK13$183
Supernus Pharmaceuticals, Inc.12$178
Eisai Inc.11$173
Biohaven Pharmaceutical Holding Company Ltd.19$161
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)10$145
Sanofi-aventis U.S. LLC8$137
Antares Pharma, Inc.9$133
Daiichi Sankyo Inc.5$102
UCB, Inc.4$98
Lundbeck LLC3$91
Neurocrine Biosciences, Inc.4$86
Biogen4$86
Alkermes, Inc.5$86
Sanofi2$84
E.r. Squibb & Sons, L.L.C.5$70
Axsome Therapeutics, Inc.4$68
Xeris Pharmaceuticals, Inc.3$63
Kowa Pharmaceuticals America, Inc.5$63
Bayer4$61
Genentech USA, Inc.3$55
Aytu Biopharma, Inc.2$52
Clarus Therapeutics Inc.4$48
Exact Sciences3$42
Grifols USA, LLC2$40
Collegium Pharmaceutical, Inc.3$39
Nestle Healthcare Nutrition Inc.2$38
Jazz Pharmaceuticals Inc.2$37
Smith+Nephew2$25
Radius Health, Inc.1$25
Ironwood Pharmaceuticals, Inc2$23
Neurelis, Inc.1$20
Exeltis, USA Inc.1$18
Ironshore Pharmaceuticals Inc.1$17
Adlon Therapeutics L.p.1$16
Arbor Pharmaceuticals, Inc.1$15
Sunovion Pharmaceuticals Inc.1$15
Novartis1$14
Impel Pharmaceuticals Inc.1$14
Zyla Life Sciences, Inc.1$13
Currax Pharmaceuticals LLC1$12
Shire North American Group Inc1$12
SK Life Science, Inc.1$12
Mylan Specialty L.p.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,045 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$97,434
Medicare patients
328
Services billed
1,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban273$128,516
OzempicSemaglutide119$122,665
MounjaroTirzepatide110$118,061
FarxigaDapagliflozin Propanediol97$79,943
XareltoRivaroxaban125$72,806
JardianceEmpagliflozin78$46,253
TrulicityDulaglutide37$41,144
Nurtec OdtRimegepant Sulfate25$34,875
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$33,325
MyrbetriqMirabegron86$33,074
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$32,701
RexultiBrexpiprazole22$30,930
ArexvyRsvpref3 Antigen/As01e/Pf91$26,732
LinzessLinaclotide19$19,741
RybelsusSemaglutide16$18,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$1,022$163,391298 claims
Lilly USA, LLCMounjaro, Trulicity$611$159,205147 claims
Novo NordiskOzempic, Rybelsus$1,149$140,942135 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,343$122,471169 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix$183$84,913212 claims
Johnson & JohnsonXarelto$345$72,806125 claims
Boehringer IngelheimJardiance, Stiolto Respimat$292$52,35191 claims
Astellas Pharma US IncMyrbetriq$569$33,07486 claims
Otsuka America Pharmaceutical, Inc.Rexulti$218$30,93022 claims
AbbVieLinzess, Namzaric$2,091$25,59830 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall$339$21,75135 claims
MerckJanuvia$237$17,48424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Jefferson City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →